Peptide · Fact sheet
Vosoritide
Also known as Voxzogo
Vosoritide is FDA approved as Voxzogo to increase linear growth in children with achondroplasia whose growth plates remain open. It is not approved as a height enhancer for children without achondroplasia or after growth plates close.
What is Vosoritide?
Vosoritide is an analog of C-type natriuretic peptide that counteracts overactive FGFR3 signaling, the central growth-plate mechanism in achondroplasia.
The approval is based on increased annualized growth velocity; final adult height and broader functional outcomes are still being studied.
Benefits people look for
It targets the biology of the most common form of disproportionate short stature rather than supplying growth hormone.
Its accelerated-approval endpoint makes the distinction between faster childhood growth and confirmed long-term clinical benefit important.
What the evidence supports
- The pivotal trial found a greater increase in annualized growth velocity than placebo over one year.
- Extension studies suggest the growth-velocity effect can persist, but confirmatory final-height evidence remains important.
All research areas
- Linear growth in achondroplasia
- Final adult height
- Body proportions and skeletal outcomes
- Function and quality of life in achondroplasia
- Final adult height and broader long-term clinical outcomes
- Other genetically defined skeletal dysplasias
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- The label warns about temporary decreases in blood pressure.
- Common adverse reactions include injection-site reactions, rash, vomiting, joint pain, decreased blood pressure, and gastroenteritis.
- Evidence in some age groups and medical situations is smaller than in the initial pivotal population.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesA randomized Phase 3 trial demonstrated improved annualized growth velocity. Evidence for final adult height and the full set of long-term health and functional outcomes is still developing.
Selected research to read
Pivotal placebo-controlled trial of annualized growth velocity in children with achondroplasia.
Controlled study informing the expanded pediatric indication.
FDA approval & research status
Voxzogo is FDA approved under accelerated approval to increase linear growth in pediatric patients with achondroplasia and open epiphyses. The FDA later removed its minimum-age restriction.
Approved uses covered here
- Increasing linear growth in pediatric patients with achondroplasia and open growth plates
FDA approved for achondroplasia growth indication
Vosoritide is FDA approved under the Voxzogo label for children with achondroplasia and open growth plates, with accelerated-approval context and follow-up evidence remaining important.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- The magnitude of any change in final adult height
- Long-term effects on function, pain, surgery, body proportions, and quality of life
- Rare harms that may emerge with longer and earlier treatment
- Whether findings extend to skeletal conditions other than achondroplasia
The takeaway
Vosoritide is a targeted rare-disease peptide with a proven effect on childhood growth velocity. The unresolved question is how that translates into final height and broader long-term outcomes.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Voxzogo
Current indication, accelerated-approval basis, warnings, and adverse reactions.
- 2fdaFDA: ongoing vosoritide accelerated approval
FDA record of the confirmatory final-adult-height requirement.
- 3pubmedRandomized Phase 3 vosoritide trial
Pivotal placebo-controlled trial of annualized growth velocity in children with achondroplasia.
- 4pubmedRandomized trial in children younger than 5
Controlled study informing the expanded pediatric indication.